Drugs /
liothyronine
Back to Drugs List
Overview
NCI Definition [1]:
A therapeutic formulation of the primary physiologically active form of endogenous thyroid hormone. In vivo, triiodothyronine enters the nucleus and binds to nuclear thyroid hormone receptors that subsequently bind to thyroid response elements (TREs) located in target genes. Receptor binding by triiodothyronine in combination with recruited coactivators results in maximal transcriptional activation after binding to TREs; in general, binding of thyroid hormone receptor alone to TREs leads to repression of gene transcription (NCI04)
Clinical Trials
Liothyronine has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating liothyronine, 1 is phase 2 (1 open).
Breast carcinoma is the most common disease being investigated in liothyronine clinical trials [2].
Drug Details
Synonyms [2]:
therapeutic triiodothyronine, triiodothyronine (substance), t3 preparation, tri-iodothyronine product, triiodothyronine, t3 - liothyronine, t3 preparation, liothyronine (product), 1297, 6893-02-3, t>3< preparation, liothyronine, l-triiodothyronine preparation, l-triiodothyronine, 3,5,3' triiodothyronine, therapeutic t3, liothyronine, t3 - triiodothyronine
NCIT ID [1]:
C907
SNOMED ID [1]:
F-B3030
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
